Biofrontera Inc. to Participate in Benchmark’s 11th Annual Discovery One-on-One Investor Conference
01 December 2022 - 6:08AM
Biofrontera
Inc. (Nasdaq: BFRI),
a biopharmaceutical company specializing in the commercialization
of dermatological products, announced today that the Company will
be participating in Benchmark’s 11th Annual Discovery One-on-One
Investor Conference being held on December 1, 2022 in New York, NY.
Erica Monaco, Chief Executive Officer, and
Hermann Lübbert, Executive Chairman of Biofrontera Inc. will be
meeting with registered investors in one-on-one meetings and
small-group sessions.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based
biopharmaceutical company commercializing a portfolio of
pharmaceutical products for the treatment of dermatological
conditions with a focus on PDT and topical antibiotics. The
Company’s licensed products are used for the treatment of actinic
keratoses, which are pre-cancerous skin lesions, as well as
impetigo, a bacterial skin infection. For more information, visit
https://www.biofrontera-us.com.
Contacts
Biofrontera Inc.Anke zur
Mühlen+1 781 486 1539us-ir@biofrontera.com
LHA Investor RelationsTirth T.
Patel+1 212 201 6614tpatel@lhai.com
# # #
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biofrontera (NASDAQ:BFRIW)
Historical Stock Chart
From Oct 2023 to Oct 2024